Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia (P<0.001) were also achieved.

Top-line results from AEGIS were presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco in a poster session titled, "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results." The study was conducted to evaluate the safety and efficacy of Soliris in Japanese patients with PNH relative to the previously reported SHEPHERD and TRIUMPH (1,2) Phase III Soliris trials, which were conducted in the United States, Europe and Australia.

"These results show clinical improvements from eculizumab for Japanese patients with PNH, consistent with those observed in the clinical trials conducted in the United States and Europe," said Yuzuru Kanakura, M.D., Ph.D., Professor of Hematology and Oncology at Osaka University Hospital in Suita, Japan, and lead author of the study. "Consistent with the results from the SHEPHERD and TRIUMPH trials, these patients experienced significant reductions in hemolysis, anemia, transfusion dependence, and fatigue. Perhaps most noteworthy was the improvement in kidney function observed with eculizumab treatment. These are important and potentially life-changing improvements for patients with PNH."

Clinical Data

In t
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... -- Stand Up To Cancer (SU2C) and the American Cancer ... Team to attack the number one cancer killer in America, ... American Association for Cancer Research (AACR), Scientific Partner to SU2C. ... the United States will be diagnosed with ... from it, making lung cancer the leading cause of cancer ...
(Date:4/20/2015)... Eli Lilly and Company (NYSE: LLY ... statistically superior to placebo in the treatment of patients ... proportion of patients achieving an ACR 20 response. ACR ... percent reduction in disease signs and symptoms as defined ... the 24-week, Phase 3 study, titled SPIRIT-P1, patients who ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... Chilcott plc (Nasdaq: WCRX ) today announced a ... certain selling shareholders. The selling shareholders include funds ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... of the Company,s senior management. The offering is ...
... Omeros Corporation (Nasdaq: OMER ), a biopharmaceutical company ... inflammation and disorders of the central nervous system, today ... Thursday, November 19, 2009 to discuss the Company,s third ... A. Demopulos, M.D., Chairman and CEO of Omeros, will ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19 2
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... 20, 2015 The American Association for ... and Safety Improvement as the 2015 winner of the ... association’s Annual Meeting, April 18, in Las Vegas, Nevada. ... team, patient safety can be dramatically improved,” said Peter ... CEO. “Northwestern Medicine and its Academy for Quality and ...
(Date:4/20/2015)... Rolling Meadows, IL (PRWEB) April 20, 2015 ... of Mutare Inc., has secured nationally-renowned Gastroenterologist Lawrence ... Medical Officer. , Dr. Kosinski brings a ... knowledge and vision to the Mutare Health ... solutions for improved communication, collaboration, and quality of ...
(Date:4/20/2015)... Lake City, Utah (PRWEB) April 20, 2015 ... End of Employer-Provided Health Insurance: Why It’s Good for ... 30, 2015. , Paul Zane Pilzer and Rick Lindquist ... of Employer-Provided Health Insurance: Why It’s Good for You ... to our nation’s employer health insurance woes - employer-funded ...
(Date:4/20/2015)... Advance Home Care Supply understands ... many customers would prefer not to share with others. As ... discreet delivery method allowing customers to order the products and ... without fear of a neighbor or passerby knowing what the ... now on all orders and no minimum order limit is ...
Breaking Medicine News(10 mins):Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 3Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3
... the San Francisco Zoo had knowingly imported parakeets with a ... human interaction //. ,While the disease is not ... virus which causes psittacine beak and feather disease could pose ... bird's immune system causing abnormal feather growth and beak deformities. ...
... by scientists to clarify with the suspected case //. ... substance for testing it with the suspected virus in the ... it has been imported from Australia and stored in vials, ... suits are engaged to deal with the dangerous substance. ...
... is major problem in the quake affected areas of Indonesia. ... contact //with the bacteria Clostridium tetani. It is otherwise ... resulting in stiffness of the jaw. If not treated properly ... recent survey it has already killed 18 earthquake survivors in ...
... outbreak of malarial attack has made people to be feared and ... spread //. This non-endemic malarial attack has not been spread through ... mosquito (female anopheles) in Bahamas. ,In Exuma, a large ... to be known by the authorities later. The Haiti country is ...
... have warned of another outbreak of bird flu in Maharashtra ... culled// in the first episode of the dreaded virus outbreak ... bird flu in the Nandurbar and Jalgaon regions, giving a ... ,If experts of the technical committee set up by ...
... different dimension to eating disorder which seems to have ... during childhood and the formative years can lead to ... into an eating disorder in women, suggesting that the ... and separation anxiety. ,Dr. Alfonso Troisi and ...
Cached Medicine News:Health News:Experts Warn of Bird Flu Recurrence in Maharashtra 2
... The SmartPulse 10.6 CO2 system was expressly ... in cosmetic surgery. A special source and ... it possible to create particular high energy ... impulses (technically known as 'top-flat shaped') allow ...
... laser is the ideal instrument for safe, ... Plus, the majority of surface lesions can ... range of scar tissue, with a minimum ... with the elimination of anaesthetics, risks and ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... and efficient method applied to dermatological therapy ... research and development with hundreds of users, ... source, but rather a platform for future ... in pulsed-light-based technology, the most valid and ...
Medicine Products: